The Health Sciences Authority (HSA), a statutory board under the Ministry of Health of the Government of Singapore, granted an interim authorization under the Pandemic Special Access Route (PSAR) for the use of AstraZeneca’s antiviral monoclonal antibody, Evusheld.
Evusheld is a drug cocktail for the treatment of COVID-19, which is a combination of two “long” antibodies that “take longer to metabolize in the body and provide longer-lasting protection for up to a year.”
“The treatment must be prescribed by a doctor and the suitability of use on the individual patient will require a careful clinical assessment by the prescribing doctor,” HSA warned.
HSA also warned that the Evusheld is not a substitute for vaccination in individuals recommended to have a COVID-19 vaccine.
Meanwhile, HSA said it would actively review the evolving effectiveness and safety data to ensure that the benefits of Evusheld continue to outweigh the risks.
“As a condition for the interim authorization under PSAR, AstraZeneca is required to collect and submit the relevant safety data from ongoing clinical studies to ensure the continued safety and efficacy of Evusheld, including its efficacy against prevailing variants,” HSA added.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.